Introduction
Abstract
Selected references
Currently available treatment options for Familial Hypercholesterolemia
JUXTAPID (lomitapide)
MTP inhibition: Mechanism of Action
Proof of Concept
LDL CHANGES WITH EZETIMIDE AND /OR LOPITAMIDE
Lomitapide HoFH Phase 3
Efficacy of lomitapide in HoFH
Lomitapide HoFH Phase 3 Study
Safety of lomitapide in HoFH
Summary of Alteration of Apheresis and LDL goals
Safety profile of lomitapide
KYNAMRO (mipomersen)
Mipomersen: Apo B-100 as a Target
ApoB Antisense Proof of Concept
Mipomersen Phase 3 Study Design
200 mg Mipomersen (SC, qw) Decreases LDL-C
Mipomersen HoFH Study
Mipomersen Efficacy From All Phase 3 Studies
Mipomersen Phase 3 Extension Study
Safety Profile of Mipomersen
Comparison of Approved Aggressive Therapies for FH
Summary of Approved Aggressive Therapies for FH
1 of 25
